Investegate |Angelfish Inv. PLC Announcements | Angelfish Inv. PLC: Notice of GM, Board Changes and Change of Adviser
Investegate announcements from Angelfish Inv. PLC, Notice of GM, Board Changes and Change of Adviser
Stay updated with breaking news from Ordinal Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Angelfish Inv. PLC, Notice of GM, Board Changes and Change of Adviser
1 : Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, today announces results from the Home Cohort of its SG016 Phase II trial of SNG001 in SARS-CoV-2 infected patients and data from the combined analysis of the Hospital and Home Cohorts. SNG001 is a formulation containing IFN-beta for nebulisation, allowing it to be delivered directly into patients’ lungs. A number of studies have reported that the SARS-CoV-2 virus suppresses natural production of IFN-beta and prevents induction of anti-viral r...
Posted: Mon Mar 15, 2021 10:15 am FireChick wrote: Eh, even if anime movies were nominated for the Oscars, we all know none of them will win anyway because people at the Oscars don't care about anime in any way. You seem to be forgetting that anime has won once for feature (Spirited Away) and once for short (Le Maison en Petite Cubes). Of the other four times that anime movies have gotten nominations, there's only maybe one case where the anime movie probably should have won: • Howl's Moving Castle (2005) was a decent movie but not (IMO) one of Ghibli's best or deserving of the award.
Proxalutamide reduces COVID-19 mortality risk by 92 percent 260 In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil. In a clinical trial, Proxalutamide reduced COVID-19 mortality risk by 92 percent and shortened the median hospital stay of patients by nine days. The investigator-initiated trial (NCT04728802), conducted by Dr Andy Goren and Dr Flávio Adsuara Cadegiani at 12 sites in the Brazil, is a placebo-controlled, double-blinded randomised parallel assignment study. The trial has two cohorts (men and women) and two ar...
A lower rate of intensive care unit admissions seen among those who received vitamin D